FGFR2 and gastric cancer: Almost a decade ago, GP369 was shown to effectively inhibit FGF7-ligand-induced FGFR2 phosphorylation, MAPK signalling and proliferation of FGFR2-amplified SNU-16 GC cells in vitro, and to inhibit their growth in vivo [110].